Ordering Recommendation

Diagnostic test for individuals with nonsyndromic hearing loss and 1 identified GJB2 variant. Carrier screening if family history of GJB6 deletion or for reproductive partner of individual with GJB6 or GJB2 variants.


Polymerase Chain Reaction/Capillary Electrophoresis




7-10 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation

Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature


Unacceptable Conditions

Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

Reference Interval
Interpretive Data

Background  Information for Hearing Loss, Nonsyndromic, Connexin 30 (GJB6) 2 Deletions:
: Moderate to profound nonsyndromic hearing loss (NSHL).
Incidence: Approximately 1 in 30 individuals with NSHL has a GJB6 deletion; 1 in 100,000 in the general population.
Inheritance: Autosomal recessive. Compound heterozygotes for GJB2 and GJB6 mutations are affected. Twenty percent of GJB2 heterozygotes with NSHL have a GJB6 deletion; homozygosity for GJB6 deletions is rare.
Cause: GJB6 gene mutations.
Mutations Tested: 309kb del(GJB6-D13S1830), previously reported as 342kb, and 232kb del(GJB6-D13S1854).
Clinical Sensitivity: Dependent on ethnicity.
Clinical Specificity: 99 percent.
Methodology: Multiplex PCR using deletion-specific primers, followed by capillary gel electrophoresis.
Analytical Sensitivity and Specificity: Greater than 99 percent.
Limitations: GJB6 mutations other than the two targeted will not be identified. The etiology of hearing loss due to other genetic or environmental causes will not be determined. Diagnostic errors can occur due to rare sequence variations.

Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Hotline History
CPT Codes


Component Test Code* Component Chart Name LOINC
2001957 Connexin 30 GJB6 Deletion 309
2001958 GJB6 DEL Specimen Type
2001959 Connexin 30 Interpretation
2002107 Connexin 30 GJB6 Deletion 232
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Connexin 30 mutation assay
  • GJB6
  • GJB6 deletions assay
Hearing Loss, Nonsyndromic, Connexin 30 (GJB6) 2 Deletions